In 2023, the global Hypophosphatasia Treatment Market is expected to be worth US$ 16.13 million. With rising alcohol consumption, the overall demand for hypophosphatasia treatment is expected to grow at a 5.0% CAGR between 2023 and 2033, reaching around US$ 26.27 million by 2033.
Furthermore, factors such as increased government and non-profit initiatives in various countries to improve public awareness about rare diseases result in a gradual increase in the diagnosis rate of unusual diseases. As a result, important variables such as favourable reimbursement policies and government finance for treatment in industrialised countries are increasing the rate of acceptance of this therapy. As a result, these factors are expected to add to the market’s revenue share throughout the forecast period.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16229
Other factors that are expected to drive market growth include an increase in the incidence of rare diseases globally, an increase in the demand for Hypophospatasia Drugs to improve the treatment of rare diseases, and an increase in government spending on healthcare infrastructure, such as favourable reimbursement for HPP. Furthermore, the increased availability of HPP therapies and the increased use of HPP drugs influence the market’s revenue share.
Moreover, focus on importance of patient safety, increase in the population, growth of awareness, improved healthcare infrastructure, and less stringent guidelines for rare diseases positively affects the growth of the hypophospatasia market. Also, advancements in the HPP therapy as well as government support for treatment extend profitable opportunity to the market players during the analysis period.
Key Takeaways from the Market Study:
•Global hypophospatasia treatment market was valued at US$ 15.36 Million by 2022-end
•From 2018 to 2022, the market demand expanded at a CAGR of 2.6%
•By Type, the Odontohypophospatasia segment of the market constitutes the bulk of the market with a market share of 48%
•By Treatment Type, the Medication segment dominates the market with a share of 47%
•From 2023 to 2033, Hypophospatasia Treatment sales are expected to flourish at a CAGR of 5.0%.
•By 2033, the market value of Hypophospatasia Treatment is expected to reach US$ 26.27 Million.
“An upsurge in financial support to researchers for developing new innovative drugs for treatment of hypophospatasia, coupled with strong product pipeline are expected to fuel the hypophospatasia treatment market over the analysis period,” remarks an FMI analyst.
Competitive Landscape:
Prominent players in the hypophospatasia treatment market are Kirin Holdings Company, Vericel Corporation, Mereo BioPharma Group plc., Novartis AG, AM Pharma B.V., Alexion, Bayer AG, Enobia Pharma, and Pfizer, Inc., among others.
Recent Developments:
•In November 2022, Rallybio, together with its partner Exscientia, has been working toward the selection of a small molecule development candidate to advance into the clinic targeting ENPP1 for the treatment of patients with hypophospatasia (HPP).
•Significant progress has been made to identify a lead compound and generate mouse in vivo biomarker evidence to support modulation of on-target activity.
Through this collaboration with a leading global HPP expert, in vivo efficacy data is expected in the second half of 2023. Following those results, both companies expect to commence investigational new drug (IND)-enabling studies.
More Valuable Insights Available
Future Market Insights offers an unbiased analysis of the global Hypophosphatasia Treatment Market, providing historical data for 2018 to 2022 and forecast statistics from 2023 to 2033.
To understand opportunities in the Hypophospatasia Treatment Market, the market is segmented on the basis of type, treatment type, and end user, across seven major regions.
Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-16229
Key Segments :
Hypophospatasia Treatment Market by Type:
•Odontohypophospatasia
•Pseudohypophospatasia
Hypophospatasia Treatment Market by Treatment Type:
•Medication
oAsfotase Alfa
oNon-steroidal Anti-inflammatory Drugs
oCalcitonin
oStrensiq
•Surgery
Hypophospatasia Treatment Market by End User:
•Hospitals
•Pharmacies
•Others
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
